Date | Price Target | Rating | Analyst |
---|---|---|---|
9/10/2024 | $56.00 | Buy | UBS |
6/21/2024 | $48.00 | Buy | Citigroup |
1/2/2024 | $30.00 | Neutral → Underperform | BofA Securities |
9/25/2023 | $40.00 → $31.00 | Neutral → Sell | Goldman |
9/7/2023 | $59.00 | Buy | Berenberg |
4/20/2023 | $35.00 | Neutral | BofA Securities |
10/14/2022 | $57.00 → $61.00 | Hold → Buy | Jefferies |
8/3/2022 | $57.00 | Buy → Hold | Jefferies |
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK) Data with PDUFA Date Expected in 2028 to Extend Pitolisant Franchise Beyond 2040 WAKIX Patent Upheld Again - U.S. Patent and Trademark Office (USPTO) Issues Final Denial After Two Attempts to Challenge the WAKIX Patent Received U.S. Food and Drug Administration (FDA) Approval and Launched WAKIX for the Treatment of EDS in Pediatric Patients with Narcolepsy Providing the First and Only Non-Scheduled Treatment Option On Track to Submit Supplemental New Drug Application for Pitolisant in Idiopa
PLYMOUTH MEETING, Pa., July 23, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report second quarter 2024 financial results on Tuesday, August 6, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 6, 2024, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial (800) 225-9448 (domestic) or (203) 518-9708 (international), and reference passcode HRMYQ224. It is recommended that you dial in at least 10 minutes prior to the call. The live and repl
WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 On Track Toward Pediatric Exclusivity to Extend WAKIX Exclusivity to September 2030: Pediatric Narcolepsy sNDA PDUFA Date of June 21, 2024; PWS Phase 3 TEMPO Study Initiated in March 2024 Pitolisant Franchise Revenue Potential Extended Beyond 2040 With Next-Generation Formulations; Reports Positive Pharmacokinetic Data on Next-Generation Formulation 1 (NG1); PDUFA Expected in 2026 Strengthens Leadership Position in Sleep/Wake with Licensing of TPM-1116, a Highly Potent and Selective O
8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
10-Q - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
UBS initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $56.00
Citigroup initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $48.00
BofA Securities downgraded Harmony Biosciences from Neutral to Underperform and set a new price target of $30.00
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.
Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
PLYMOUTH MEETING, Pa., Jan. 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another opportunity. The Harmony Board of Directors has named Jeffrey M. Dayno, MD, Harmony's Executive Vice President and Chief Medical Officer, as interim CEO effective immediately. Jeff Aronin, Harmony's founder and Board chairman, will continue to lead the Board of Directors as well as
PLYMOUTH MEETING, Pa., Nov. 22, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Linda Szyper to the Company's Board of Directors. Ms. Szyper brings extensive healthcare and pharmaceutical knowledge with expertise anchored in more than 30 years of experience that spans both pharmaceutical sales and marketing as well as healthcare communications services. Mos
PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the appointment of John C. Jacobs, President and CEO of Harmony, to the Life Sciences Pennsylvania's (LSPA) Board of Directors, effective May 6, 2021. John Jacobs' election to the board is accompanied by other leaders representing the breadth, diversity and geographic reach of LS
PLYMOUTH MEETING, Pa., Aug. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Wells Fargo 2024 Healthcare Conference Location: BostonFireside Chat: Thursday, September 5, 2024, at 9:30 a.m. ET2024 Cantor Global Healthcare Conference Location: New York CityFireside Chat: Tuesday, September 17, 2024, at 3:05 p.m. ETA webcast of the fireside chats will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/.
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK) Data with PDUFA Date Expected in 2028 to Extend Pitolisant Franchise Beyond 2040 WAKIX Patent Upheld Again - U.S. Patent and Trademark Office (USPTO) Issues Final Denial After Two Attempts to Challenge the WAKIX Patent Received U.S. Food and Drug Administration (FDA) Approval and Launched WAKIX for the Treatment of EDS in Pediatric Patients with Narcolepsy Providing the First and Only Non-Scheduled Treatment Option On Track to Submit Supplemental New Drug Application for Pitolisant in Idiopa
- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo